41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.
Kezar Life Sciences
5
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.
The University of Adelaide
38
Structure-based design ofß1i orß5i specific inhibitors of human immunoproteasomes.
Leiden Institute of Chemistry and Netherlands Proteomics Centre
14
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.
Weill Cornell Medical College
20
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
Hokkaido University
5
Molecular mechanisms of acquired proteasome inhibitor resistance.
University of California San Diego
12
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Proteolix
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
26
Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.
Chinese Academy of Medical Sciences & Peking Union Medical College
19
Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor.
Mitsubishi Tanabe Pharma
32
Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.
Weill Cornell Medicine
50
Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Peking Union Medical College
42
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
Merck
23
Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.
Weill Cornell Medicine
3
Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp.
Kumamoto University
22
Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Zhejiang University
21
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
University of Kentucky
46
Discovery of selective fragment-sized immunoproteasome inhibitors.
Hungarian Academy of Sciences
33
A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Tsinghua University
42
Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.
Weill Cornell Medicine
5
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
University of Melbourne
22
Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Hangzhou Xixi Hospital
41
LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.
University of Kentucky
33
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Hangzhou Institute of Innovative Medicine
12
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
Zhejiang University
12
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Kezar Life Sciences
14
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Hangzhou Xixi Hospital
17
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.
Leiden Institute of Chemistry and Netherlands Proteomics Centre
1
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
Purdue University
31
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Zhejiang University
2
Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.
Kumamoto University
27
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
New Mexico Institute of Mining and Technology
29
Structure-based design of human immuno- and constitutive proteasomes inhibitors.
University of Rennes 1
15
Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.
University of Glasgow
45
Heterocyclic derivatives and their use in the treatment of neurological disorders
Novartis